IP Library Patent Application 11433626
Patent Application
App. No. 11/433,626

Methods and compositions for improving cognition

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/433,626
Abstract

This invention encompasses methods of improving cognitive performance and of treating, preventing and managing various diseases and disorders, such as Alzheimer's disease, autism, cognitive disorders, dementia, learning disorders, and short- and long-term memory loss.

Claims (103)

1 . A method of improving the cognitive performance of a patient, which comprises decreasing proline transporter activity in the patient.

2 . The method of claim 1 , wherein the improved cognitive performance is enhanced learning, improved comprehension, improved reasoning, or improved short- and/or long-term memory.

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . The method of claim 1 , wherein the proline transporter is encoded by human gene SLC6A7.

7 . The method of claim 1 , wherein the activity is decreased by administering to the patient an effective amount of a compound that inhibits the proline transporter.

8 . The method of claim 7 , wherein the compound is a specific proline transporter inhibitor.

9 . The method of claim 7 , wherein the compound is of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is an optionally substituted non-aromatic heterocycle;

each of D 1 and D 2 is independently N or CR 1 ;

each of E 1 , E 2 and E 3 is independently N or CR 2 ;

X is optionally substituted heteroaryl; Y is O, C(O), CH(OH), or CH 2 ;

each R 1 is independently hydrogen, halogen, cyano, R A , OR A , C(O)R A , C(O)OR A , C(O)N(R A R B ), N(R A R B ), or SO 2 R A ;

each R 2 is independently hydrogen, halogen, cyano, R A , OR A , C(O)R A , C(O)OR A , C(O)N(R A R B ), N(R A R B ), or SO 2 R A ;

each R A is independently hydrogen or optionally substituted alkyl, aryl, arylalkyl, alkylaryl, heterocycle, heterocycle-alkyl, or alkyl-heterocycle;

and each R B is independently hydrogen or optionally substituted alkyl, aryl, arylalkyl, alkylaryl, heterocycle, heterocycle-alkyl, or alkyl-heterocycle.

10 . The method of claim 7 , wherein the compound is of formula II:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is an optionally substituted non-aromatic heterocycle;

each of D 1 and D 2 is independently N or CR 1 ;

each of E 1 , E 2 and E 3 is independently N or CR 2 ;

each of G 1 and G 2 are independently N or CR 3 ;

each of J 1 , J 2 and J 3 are independently N or CR 4 ; Y is O, C(O), CH(OH), or CH 2 ;

each R 1 is independently hydrogen, halogen, or (C 1-10 )alkyl;

each R 2 is independently halogen, cyano, R 2A , OR 2A , or SO 2 R 2A ;

each R 2A is independently hydrogen or (C 1-10 )alkyl optionally substituted with one or more halogens;

each R 3 is independently hydrogen, cyano, or (C 1-10 )alkyl optionally substituted with one or more halogens;

and each R 4 is independently hydrogen, cyano, or (C 1-10 )alkyl optionally substituted with one or more halogens.

11 . The method of claim 7 , wherein the compound is of formula III:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently halogen, amine, hydroxy, alkoxy, or optionally substituted alkyl, aryl or heterocycle;

R 4 and R 5 are each independently hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle, or taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle;

and n is 0 to 5.

12 . The method of claim 7 , wherein the compound is of formula IV:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently halogen, amine, hydroxy, alkoxy, or optionally substituted alkyl, aryl or heterocycle;

R 4 and R 5 are each independently hydrogen, or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle, or taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle;

and n is 0 to 5.

13 . The method of claim 7 , wherein the compound is of formula V:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently halogen, amine, hydroxy, alkoxy, or optionally substituted alkyl, aryl or heterocycle;

R 4 and R 5 are each independently hydrogen, or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle, or taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle;

and n is 0 to 5.

14 . (canceled)

15 . (canceled)

16 . A method of improving the cognitive performance of a patient, which comprises administering to the patient an effective amount of a compound that inhibits the proline transporter.

17 . The method of claim 16 , wherein the improved cognitive performance is enhanced learning, improved comprehension, improved reasoning, or improved short- and/or long-term memory.

18 . (canceled)

19 . (canceled)

20 . (canceled)

21 . The method of claim 16 , wherein the proline transporter is encoded by human gene SLC6A7.

22 . The method of claim 16 , wherein the compound is a specific proline transporter inhibitor.

23 . The method of claim 16 , wherein the compound is of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is an optionally substituted non-aromatic heterocycle;

each of D 1 and D 2 is independently N or CR 1 ;

each of E 1 , E 2 and E 3 is independently N or CR 2 ;

X is optionally substituted heteroaryl; Y is O, C(O), CH(OH), or CH 2 ;

each R 1 is independently hydrogen, halogen, cyano, R A , OR A , C(O)R A , C(O)OR A , C(O)N(R A R B ), N(R A R B ), or SO 2 R A ;

each R 2 is independently hydrogen, halogen, cyano, R A , OR A , C(O)R A , C(O)OR A , C(O)N(R A R B ), N(R A R B ), or SO 2 R A ;

each R A is independently hydrogen or optionally substituted alkyl, aryl, arylalkyl, alkylaryl, heterocycle, heterocycle-alkyl, or alkyl-heterocycle;

and each R B is independently hydrogen or optionally substituted alkyl, aryl, arylalkyl, alkylaryl, heterocycle, heterocycle-alkyl, or alkyl-heterocycle.

24 . The method of claim 16 , wherein the compound is of formula II:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

A is an optionally substituted non-aromatic heterocycle;

each of D 1 and D 2 is independently N or CR 1 ;

each of E 1 , E 2 and E 3 is independently N or CR 2 ;

each of G 1 and G 2 are independently N or CR 3 ;

each of J 1 , J 2 and J3 are independently N or CR 4 ; Y is O, C(O), CH(OH), or CH 2 ;

each R 1 is independently hydrogen, halogen, or (C 1-10 )alkyl;

each R 2 is independently halogen, cyano, R 2A , OR 2A , or SO 2 R 2A ;

each R 2A is independently hydrogen or (C 1-10 )alkyl optionally substituted with one or more halogens;

each R 3 is independently hydrogen, cyano, or (C 1-10 )alkyl optionally substituted with one or more halogens;

and each R 4 is independently hydrogen, cyano, or (C 1-10 )alkyl optionally substituted with one or more halogens.

25 . The method of claim 16 , wherein the compound is of formula III:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently halogen, amine, hydroxy, alkoxy, or optionally substituted alkyl, aryl or heterocycle;

R 4 and R 5 are each independently hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle, or taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle;

and n is 0 to 5.

26 . The method of claim 16 , wherein the compound is of formula IV:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently halogen, amine, hydroxy, alkoxy, or optionally substituted alkyl, aryl or heterocycle;

R 4 and R 5 are each independently hydrogen, or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle, or taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle;

and n is 0 to 5.

27 . The method of claim 16 , wherein the compound is of formula V:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is hydrogen or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently halogen, amine, hydroxy, alkoxy, or optionally substituted alkyl, aryl or heterocycle;

R 4 and R 5 are each independently hydrogen, or optionally substituted alkyl, aryl, heterocycle, alkyl-aryl or alkyl-heterocycle, or taken together with the nitrogen atom to which they are attached, form an optionally substituted heterocycle;

and n is 0 to 5.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 14, 2020
From: BIOPHARMA CREDIT PLC
To: LEXICON PHARMACEUTICALS, INC.
Reel/Frame 053767/0445 →
SECURITY INTEREST Recorded Dec 20, 2017
From: LEXICON PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 044958/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2006
From: BARBOSA, JOSEPH; DONG, LI; FINK, CYNTHIA ANNE; LANTHORN, THOMAS HERBERT; WANG, JIANCHENG; ZIPP, G. GREGORY
To: LEXICON GENETICS INCORPORATED
Reel/Frame 018024/0232 →